Abstract
The multiple sclerosis (MS) market has total global revenues of over $6bn in
2008. Those revenues will exceed $9bn during the second half of next decade,
our new study shows. The World Health Organization estimates that over 2.5
million people suffer from multiple sclerosis worldwide. The prevalence and
onset of MS in children and adults is expected to rise steadily. Global sales
for MS therapies will rise accordingly, due to epidemiological, healthcare and
commercial drivers. In this new market-based study - The Global Multiple
Sclerosis Market 2009-2024 - we show and explain those trends in detail. This
report will provide you with the analytical information that you need to
understand current trends and future directions in the MS market area, the
successful drugs being introduced and where the future successful growth of
the market lies.
The Global Multiple Sclerosis Market 2009-2024 commercially analyses both
leading and emergent treatments, with key companies and products discussed
comprehensively. In particular, we discuss prospects for the following MS
drugs:
- Tysabri
- Avonex
- Copaxone
- Betaferon
- Rebif.
Contemporary disease-modifying drugs for MS are administered intravenously,
intramuscularly or subcutaneously, typically with discomfort to patients. We
believe that orally-administered MS products will change the dynamics of the
market area significantly. But you must understand now the commercial
opportunities for those new agents and other exciting pipeline developments.
This report answers those important questions and others, such as how the
established MS products will fare competitively in the years ahead. Which will
remain the most profitable and how will they be affected by new competition.
Comprehensive Market Analysis
The Global Multiple Sclerosis Market 2009-2024 examines the market sector
critically through a comprehensive review of information sources, including
first-hand primary consultations with relevant experts. This report provides
detailed sales forecasts, discussions of pipeline developments and analyses of
important contemporary issues, especially relevant commercial drivers and
restraints. Sources used include gold-standard commercial databases, in-house
analytical tool, industry news, published reports, policy documents and
economic research. Importantly, visiongain applies rigorous financial
forecasting, qualitative analyses and the assessment of unmet needs. The
result is a comprehensive market- and industry-centred report with detailed
analysis and informed opinion.
Why you should buy the Global Multiple Sclerosis Market 2009-2024 By purchasing this report, you will receive the following benefits:
Predicted revenues, growth rates and other key metrics for the global MS drugs
market from 2009 to 2024 Predicted revenues, growth rates and other key
metrics for leading MS drugs worldwide from 2009 to 2024 Predicted revenues,
growth rates and other key metrics for MS drug sales in leading nations from
2009 to 2024 Expert opinions from original visiongain interviews, with full
interview transcripts - you will not find this information anywhere else
Discussion of hot pipeline developments and up-and-coming products Discussion
of forces that influence and characterise the market for MS treatments
worldwide:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats
Discussion of where the market is heading overall - both technologically and
commercially - from the present onwards.
| 
View Cart
